Sonja Christis Email

Manager CMC RA . Xenikos

Current Roles

Employees:
2
Revenue:
$310k
About
Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on conjugated antibodies, designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos' flagship product, T-Guard®, is being prepared to enter Phase 3 testing for the treatment of acute graft-versus-host-disease.
Xenikos Address
Wilhelminasingel 14
Nijmegen, null
Xenikos Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.